Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Pfizer Limited, Ramsgate Road, Sandwich Kent, CT13 9NJ, United Kingdom
Dalacin T Topical Solution.
| Pharmaceutical Form |
|---|
|
Topical solution. Clear colourless aqueous solution. |
One ml of Dalacin T Topical Solution contains the equivalent of 10 mg Clindamycin.
Excipients with known effect: Propylene glycol 50 mg/ml.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive aerobes and a wide range of anaerobic bacteria. Lincosamides such as clindamycin bind to the 50S subunit of the bacterial ribosome and inhibit the early stages of protein synthesis. |
| List of Excipients |
|---|
|
Isopropyl alcohol |
Bottle: White high density polyethylene bottle containing 30 ml, 50 ml or 60 ml.
Cap: Prolypropylene, linerless screw caps or Polypropylene screw caps lined with laminated films consisting of polyethylene, polyvinylidene chloride (PVdc) and polyethylene.
Applicator: Low-density polyethylene applicator made by Dab-O-Matic.
Not all pack sizes may be marketed.
Pfizer Limited, Ramsgate Road, Sandwich Kent, CT13 9NJ, United Kingdom
PL 00057/0962
Date of first authorisation: 18th January 1988
Date of latest renewal of authorisation: 7th August 2009
| Drug | Countries | |
|---|---|---|
| DALACIN T | Estonia, Hong Kong, Ireland, Japan, Mexico, Netherlands, Poland, Singapore, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.